An in vitro vascularized micro-tumor model of human colorectal cancer recapitulates in vivo responses to standard-of-care therapy

Around 95% of anti-cancer drugs that show promise during preclinical study fail to gain FDA-approval for clinical use. This failure of the preclinical pipeline highlights the need for improved, physiologically-relevant in vitro models that can better serve as reliable drug-screening and disease mode...

Full description

Saved in:

Bibliographic Details
Published in:	Lab on a chip Vol. 21; no. 7; p. 1333
Main Authors:	Hachey, Stephanie J, Movsesyan, Silva, Nguyen, Quy H, Burton-Sojo, Giselle, Tankazyan, Ani, Wu, Jie, Hoang, Tuyen, Zhao, Da, Wang, Shuxiong, Hatch, Michaela M, Celaya, Elizabeth, Gomez, Samantha, Chen, George T, Davis, Ryan T, Nee, Kevin, Pervolarakis, Nicholas, Lawson, Devon A, Kessenbrock, Kai, Lee, Abraham P, Lowengrub, John, Waterman, Marian L, Hughes, Christopher C W
Format:	Journal Article
Language:	English
Published:	England 07-04-2021
Subjects:	Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Colorectal Neoplasms - drug therapy Drug Evaluation, Preclinical Humans Lab-On-A-Chip Devices Tumor Microenvironment
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Around 95% of anti-cancer drugs that show promise during preclinical study fail to gain FDA-approval for clinical use. This failure of the preclinical pipeline highlights the need for improved, physiologically-relevant in vitro models that can better serve as reliable drug-screening and disease modeling tools. The vascularized micro-tumor (VMT) is a novel three-dimensional model system (tumor-on-a-chip) that recapitulates the complex human tumor microenvironment, including perfused vasculature, within a transparent microfluidic device, allowing real-time study of drug responses and tumor-stromal interactions. Here we have validated this microphysiological system (MPS) platform for the study of colorectal cancer (CRC), the second leading cause of cancer-related deaths, by showing that gene expression, tumor heterogeneity, and treatment responses in the VMT more closely model CRC tumor clinicopathology than current standard drug screening modalities, including 2-dimensional monolayer culture and 3-dimensional spheroids.
ISSN:	1473-0189
DOI:	10.1039/d0lc01216e